Lipoprotein(a): Role in atherosclerosis and new treatment options
Atherosclerosis is a chronic process characterized by inflammation and the progressive accumulation of inflammatory cells and lipids in the blood vessel wall, resulting in narrowing of the blood vessel’s circumference. Treatment of people with dyslipidemia aims to reduce the risk of developing ather...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Association of Basic Medical Sciences of Federation of Bosnia and Herzegovina
2023-07-01
|
| Series: | Biomolecules & Biomedicine |
| Subjects: | |
| Online Access: | https://www.bjbms.org/ojs/index.php/bjbms/article/view/8992 |
| _version_ | 1797261379519905792 |
|---|---|
| author | Dragana Tomic Naglic Mia Manojlovic Sladjana Pejakovic Kristina Stepanovic Jovana Prodanovic Simeunovic |
| author_facet | Dragana Tomic Naglic Mia Manojlovic Sladjana Pejakovic Kristina Stepanovic Jovana Prodanovic Simeunovic |
| author_sort | Dragana Tomic Naglic |
| collection | DOAJ |
| description | Atherosclerosis is a chronic process characterized by inflammation and the progressive accumulation of inflammatory cells and lipids in the blood vessel wall, resulting in narrowing of the blood vessel’s circumference. Treatment of people with dyslipidemia aims to reduce the risk of developing atherosclerotic disease and prevent major adverse cardiovascular events (MACE). The results of previous studies indicated that lipoprotein(a) (Lp(a)) is a critical causal factor in the estimated risk of developing a cardiovascular (CV) incident even after achieving desirable low-density lipoprotein (LDL) cholesterol levels. Lp(a) is a low-density lipoprotein particle, like LDL cholesterol. The levels of Lp(a) in plasma are genetically determined. Lp(a) catabolism is still controversial. The pathogenic potential of Lp(a) can be divided into three categories: promotion of plaque formation, thrombogenicity, and proinflammatory effects. Lp(a) levels above the 75th percentile reduced the risk of aortic valve stenosis and myocardial infarction, whereas higher levels (above 90th percentile) were associated with an increased risk of heart failure. However, no hypolipidemic agents have been approved for targeted use in patients with high Lp(a) levels. There are insufficient randomized controlled trials assessing CV outcomes that would support the evidence that current treatment options, which effectively lower Lp(a) levels, also effectively prevent CV event. However, according to some studies, there is strong evidence that better CV outcome is one of the benefits of such therapy. The results of ongoing clinical trials are eagerly awaited.
|
| first_indexed | 2024-04-24T23:40:17Z |
| format | Article |
| id | doaj.art-92c9d3631bb845968061544b19a04f11 |
| institution | Directory Open Access Journal |
| issn | 2831-0896 2831-090X |
| language | English |
| last_indexed | 2024-04-24T23:40:17Z |
| publishDate | 2023-07-01 |
| publisher | Association of Basic Medical Sciences of Federation of Bosnia and Herzegovina |
| record_format | Article |
| series | Biomolecules & Biomedicine |
| spelling | doaj.art-92c9d3631bb845968061544b19a04f112024-03-15T13:22:27ZengAssociation of Basic Medical Sciences of Federation of Bosnia and HerzegovinaBiomolecules & Biomedicine2831-08962831-090X2023-07-0123410.17305/bb.2023.8992Lipoprotein(a): Role in atherosclerosis and new treatment optionsDragana Tomic Naglic0Mia Manojlovic1https://orcid.org/0000-0001-5176-5650Sladjana Pejakovic2https://orcid.org/0000-0002-9654-6395Kristina Stepanovic3https://orcid.org/0000-0002-3736-7661Jovana Prodanovic Simeunovic4Faculty of Medicine in Novi Sad, University of Novi Sad, Novi Sad, Serbia; Clinic for Endocrinology, Diabetes and Metabolic Disorders, Clinical Center of Vojvodina, Novi Sad, SerbiaFaculty of Medicine in Novi Sad, University of Novi Sad, Novi Sad, Serbia; Clinic for Endocrinology, Diabetes and Metabolic Disorders, Clinical Center of Vojvodina, Novi Sad, SerbiaFaculty of Medicine in Novi Sad, University of Novi Sad, Novi Sad, Serbia; Clinic for Endocrinology, Diabetes and Metabolic Disorders, Clinical Center of Vojvodina, Novi Sad, SerbiaFaculty of Medicine in Novi Sad, University of Novi Sad, Novi Sad, Serbia; Clinic for Endocrinology, Diabetes and Metabolic Disorders, Clinical Center of Vojvodina, Novi Sad, SerbiaFaculty of Medicine in Novi Sad, University of Novi Sad, Novi Sad, Serbia; Clinic for Endocrinology, Diabetes and Metabolic Disorders, Clinical Center of Vojvodina, Novi Sad, SerbiaAtherosclerosis is a chronic process characterized by inflammation and the progressive accumulation of inflammatory cells and lipids in the blood vessel wall, resulting in narrowing of the blood vessel’s circumference. Treatment of people with dyslipidemia aims to reduce the risk of developing atherosclerotic disease and prevent major adverse cardiovascular events (MACE). The results of previous studies indicated that lipoprotein(a) (Lp(a)) is a critical causal factor in the estimated risk of developing a cardiovascular (CV) incident even after achieving desirable low-density lipoprotein (LDL) cholesterol levels. Lp(a) is a low-density lipoprotein particle, like LDL cholesterol. The levels of Lp(a) in plasma are genetically determined. Lp(a) catabolism is still controversial. The pathogenic potential of Lp(a) can be divided into three categories: promotion of plaque formation, thrombogenicity, and proinflammatory effects. Lp(a) levels above the 75th percentile reduced the risk of aortic valve stenosis and myocardial infarction, whereas higher levels (above 90th percentile) were associated with an increased risk of heart failure. However, no hypolipidemic agents have been approved for targeted use in patients with high Lp(a) levels. There are insufficient randomized controlled trials assessing CV outcomes that would support the evidence that current treatment options, which effectively lower Lp(a) levels, also effectively prevent CV event. However, according to some studies, there is strong evidence that better CV outcome is one of the benefits of such therapy. The results of ongoing clinical trials are eagerly awaited. https://www.bjbms.org/ojs/index.php/bjbms/article/view/8992Lipoprotein(a) (Lp(a))lipidsatherosclerosismajor adverse cardiovascular events (MACE)cardiovascular (CV) diseasescardiovascular prevention |
| spellingShingle | Dragana Tomic Naglic Mia Manojlovic Sladjana Pejakovic Kristina Stepanovic Jovana Prodanovic Simeunovic Lipoprotein(a): Role in atherosclerosis and new treatment options Biomolecules & Biomedicine Lipoprotein(a) (Lp(a)) lipids atherosclerosis major adverse cardiovascular events (MACE) cardiovascular (CV) diseases cardiovascular prevention |
| title | Lipoprotein(a): Role in atherosclerosis and new treatment options |
| title_full | Lipoprotein(a): Role in atherosclerosis and new treatment options |
| title_fullStr | Lipoprotein(a): Role in atherosclerosis and new treatment options |
| title_full_unstemmed | Lipoprotein(a): Role in atherosclerosis and new treatment options |
| title_short | Lipoprotein(a): Role in atherosclerosis and new treatment options |
| title_sort | lipoprotein a role in atherosclerosis and new treatment options |
| topic | Lipoprotein(a) (Lp(a)) lipids atherosclerosis major adverse cardiovascular events (MACE) cardiovascular (CV) diseases cardiovascular prevention |
| url | https://www.bjbms.org/ojs/index.php/bjbms/article/view/8992 |
| work_keys_str_mv | AT draganatomicnaglic lipoproteinaroleinatherosclerosisandnewtreatmentoptions AT miamanojlovic lipoproteinaroleinatherosclerosisandnewtreatmentoptions AT sladjanapejakovic lipoproteinaroleinatherosclerosisandnewtreatmentoptions AT kristinastepanovic lipoproteinaroleinatherosclerosisandnewtreatmentoptions AT jovanaprodanovicsimeunovic lipoproteinaroleinatherosclerosisandnewtreatmentoptions |